Pyrazinamide kills tuberculosis by acidifying bacterial interiors

Tuberculosis remains a major global infectious disease, and one of the oldest drugs used against it is pyrazinamide. Despite its long use, scientists have debated how Pyrazinamide actually sterilizes Mycobacterium tuberculosis inside the body. In new work led by Pierre Santucci, researchers carried out the first comprehensive side-by-side investigation of the two models that have been proposed to explain PZA’s unique mode of action. The goal was straightforward: test the competing ideas directly and see which best matches experimental evidence. To do this the team focused strictly on how PZA behaves under different conditions and whether its activity depends on pH. By comparing the models under the same experimental framework and using carefully controlled growth conditions, the study aimed to resolve longstanding discrepancies in the literature. The result is a revisited biological model that offers a clearer picture of how PZA exerts its sterilizing activity against tuberculosis bacteria.

The researchers tested the competing explanations in parallel and paid close attention to the chemical fate of PZA and how that fate affects bacteria. Their results indicate that PZA is converted into HPOA, which in turn acts as a conventional weak acid. That weak-acid behavior facilitates membrane permeation and leads to cytosolic acidification inside Mycobacterium tuberculosis. Importantly, the team used custom-based culture media to show that PZA displays heterogeneous efficacy depending on media composition, meaning that the environment in which bacteria are grown strongly influences how well PZA works. Putting these observations together, the study univocally supports a pH-dependent mechanism of action underlying PZA sterilizing activity. These findings were reached without invoking other mechanisms and preserve the exact drug and compound names reported in the study: PZA and HPOA.

The implications of this work are practical and conceptual. By showing that the pH-dependent conversion of PZA into HPOA drives membrane permeation and cytosolic acidification, the study explains why past experiments produced conflicting results and why laboratory conditions matter. The demonstration that PZA’s efficacy is heterogeneous across custom-based culture media suggests that standard testing conditions can misrepresent how the drug behaves in different environments. That insight leads naturally to a revisited biological model for PZA action and points toward design principles for next-generation PZA-like drugs that aim to reproduce or improve the same sterilizing activity. Overall, the work narrows the field of plausible mechanisms and provides a clearer target for researchers seeking more effective treatments against tuberculosis.